11.70
+8.33%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xspray Pharma publ
Its shares trade on Nasdaq Stockholm under the ticker XSPRAY.ST. It has been listed since 28 September 2017. In the fiscal year to 31 December 2018, it reported revenue of SEK 277,000 and a net loss of SEK 23.1m. At that date it held total assets of SEK 312.5m and shareholders' equity of SEK 301.7m.
Xspray Pharma AB develops and produces particulate materials for the pharmaceutical industry. The company is headquartered in Solna, Stockholm. The company went IPO on 2017-09-28. The company employs technology platform in order to create a pipeline of anti-cancer products. The firm primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Sept 2017
- Employees
- 18
- Website
- xspraypharma.com ↗
Leadership
Pay as last reported
- Dr. Anders EkblomChairman of the BoardSEK 550,000
- Mr. Per AnderssonChief Executive OfficerSEK 4.3m
- Mr. Niklas AdenborgChief Financial Officer
- Ms. Linda GlimbergChief Operating Officer
- Ms. Anette AbrahamssonSenior Vice President - Regulatory Affairs
- Mr. Christer HallgrenSenior Vice President - Intellectual Property
- Ms. Charlotta LiljebrisSenior Vice President - Research and Development
- Ms. Kerstin HasselgrenHead of Investor Relations
- Mr. Edward JordanChief Commercial Officer
- Mr. Anders BladhDirectorSEK 273,000
- Mr. Markus HaeberleinIndependent Director
- Ms. Christine LindIndependent DirectorSEK 293,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 44
- Social
- 19
- Governance
- 67
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- XSpray Pharma AB (publ) has several strengths that give it a competitive advantage in the pharmaceutical industry. One of its strengths is its innovative drug delivery technology, which allows for improved bioavailability and patient compliance.
- Another strength is its strong intellectual property portfolio, providing protection for its developed technologies and products. This allows XSpray Pharma AB to maintain a unique position in the market and prevent competitors from easily replicating its products.
- Additionally, XSpray Pharma AB has a highly skilled and experienced team of researchers and scientists, ensuring the company's ability to develop and commercialize new and effective pharmaceutical products.
Weaknesses
- Despite its strengths, XSpray Pharma AB faces certain weaknesses that pose challenges to its overall performance. One weakness is its relatively small size and limited financial resources compared to larger pharmaceutical companies. This may restrict its ability to fully exploit market opportunities and compete effectively.
- Another weakness is the dependency on a small number of key patents and products. If any of these patents expire or products fail to gain market acceptance, it could have a significant negative impact on XSpray Pharma AB's revenue and profitability.
- Furthermore, the company operates in a highly regulated industry, which can lead to lengthy and costly approval processes for its products. This can delay market entry and increase development expenses.
Opportunities
- XSpray Pharma AB has several opportunities that it can capitalize on to drive growth and success. The increasing demand for more effective and convenient drug delivery methods presents a significant opportunity for the company's innovative technology.
- Additionally, the growing global pharmaceutical market provides a favorable environment for XSpray Pharma AB to expand its customer base and increase its market share.
- Furthermore, partnerships and collaborations with larger pharmaceutical companies can enable XSpray Pharma AB to leverage their resources and reach a broader market.
Threats
- XSpray Pharma AB must also consider various threats that could impact its business operations and sustainability. One threat is intense competition from other pharmaceutical companies that also focus on drug delivery technologies or offer similar products.
- Regulatory changes and requirements imposed by authorities may pose challenges to XSpray Pharma AB's product development and commercialization plans. Compliance with these regulations can be time-consuming and expensive.
- Moreover, the potential emergence of disruptive technologies or alternative drug delivery methods could pose a threat to XSpray Pharma AB's market position if they gain widespread acceptance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.